Status:
COMPLETED
PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure in the Inpatient Setting
Lead Sponsor:
Yale University
Collaborating Sponsors:
AstraZeneca
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A randomized single-blind interventional trial to test the effectiveness of an electronic medical record-based best practice alert recommending evidence-based medical therapies versus usual care in in...
Detailed Description
Heart failure (HF) is the major cause of healthcare expenditure, morbidity, and mortality in the United States. HF is the primary diagnosis for hospital discharge in \~1 million and a secondary diagno...
Eligibility Criteria
Inclusion
- Adults ≥18 years admitted to a hospital within the Yale New Haven Hospital system (either Yale New Haven Hospital, St. Raphael's Campus, Greenwich Hospital, or Bridgeport Hospital).
- Have HFrEF defined as:
- NT-pro-BNP \>500 pg/ml within 24 hours of admission
- On IV loop diuretic within 24 hours of admission
- Left ventricular ejection fraction ≤40% (most recent)
Exclusion
- Patients within 48 hours of admission
- Patients in the intensive care unit
- Patients on hospice service
- Patients receiving intravenous milrinone
- Patient on NPO (nothing by mouth) order
- Patients on all evidence based medical therapy for HFrEF (on all 4 classes of evidence based medical therapy: beta-blockers, ACEi/ARB/ARNI, MRA, SGLT2i)
- Opted out of medical record research
Key Trial Info
Start Date :
July 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
1012 Patients enrolled
Trial Details
Trial ID
NCT04686604
Start Date
July 7 2021
End Date
June 30 2023
Last Update
January 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale New Haven Hospital
New Haven, Connecticut, United States, 06512